Great prospects for development, both in the short and in the long run

A stable and balanced shareholding structure

Alzprotect’s capital is distributed in a balanced manner between founders, public supports and private institutional investors.

• University of Lille

• Finorpa

  Fund specialized in financial support for companies in the Hauts-de-France region, manages € 90 million of capital.

• Finovam

  Public investment fund.

• Nord France Amorçage

  Investment fund backed by the Hauts de France region, through seed capital.

• Xerys Gestion

  Portfolio management company specialized in investment capital.

• Private investors

A solid financial basis to complete a first phase 2 study

Alzprotect raised a total of over 20 million euros, including 14 million € in 2017 to finance the conduct of a first phase 2 study to prove and measure the efficacy of AZP2006 in the treatment of Progressive Supranuclear Palsy.

History of financing rounds

• Seed (2008-2012): 1.595 million €
• 2014: Series A financing round of 2.66 million € from Finovam and Nord France Amorçage, and a repayable advance of 1 million € (BPI France)
• 2016: Series A: 2.163 million euros
• 2017: Series B financing round of 14 million € (Xerys Gestion)

Complementary markets

Progressive Supranuclear Palsy (PSP) – an orphan disease and a significant market

Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease that shares multiple common pathophysiological mechanisms with Alzheimer’s disease.

Symptoms include progressive loss of balance, vision disorders, changes in behavior, mood swings and speech disorders.

This rapidly progressive disease offers a life expectancy of only 5 to 7 years.

There is currently no treatment available for this condition.

The prevalence of PSP is rather high for a rare disease. Statistics vary from 1 case per 16,000 to 1 case per 100,000.

It currently affects 3,000 to 10,000 patients in France, and 25,000 patients in the United States.

PSP represents a potential annual market of over 700 million euros worldwide.

AZP2006 was granted the “orphan drug” designation by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for this disease.  

This double recognition will facilitate and accelerate the development of the molecule, giving it several commercial benefits:

• In the US: a seven-year period of marketing exclusivity, waiver of certain fees due to the Food and Drug Administration, and tax credits available for clinical trials.
• In Europe: eligibility for certain grants, reduced administrative costs, and faster clinical developments.

Alzheimer’s disease: a widespread, fast-growing market

Alzheimer’s disease is the most common form of dementia. It accounts for 50 to 80% of all cases. Its incidence and prevalence are steadily increasing: it is thought to affect some 50 million people worldwide, and around one million people in France where it is the fourth major cause of mortality.

The estimated cost of this disease in terms of public health (diagnosis and social and medical care) was 818 billion USD in 2015 worldwide.

Among these expenses, the market of pharmaceutical molecules for the treatment of Alzheimer’s disease is worth approximately 3.64 billion USD and is expected to increase by 8% every year until 2024.